Cargando…
Evaluation of the Safety, Tolerability, and Pharmacokinetic Profiles of TP0473292 (TS-161), A Prodrug of a Novel Orthosteric mGlu2/3 Receptor Antagonist TP0178894, in Healthy Subjects and Its Antidepressant-Like Effects in Rodents
BACKGROUND: TP0473292 (the active ingredient of TS-161) is a prodrug of a novel metabotropic glutamate (mGlu) 2/3 receptor antagonist being developed for the treatment of patients with depression. This study evaluated the safety, tolerability, and pharmacokinetics of orally administered TS-161 in he...
Autores principales: | Watanabe, Mai, Marcy, Brian, Hiroki, Ayano, Watase, Hirotaka, Kinoshita, Kohnosuke, Iijima, Michihiko, Marumo, Toshiyuki, Zarate, Carlos A, Chaki, Shigeyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832229/ https://www.ncbi.nlm.nih.gov/pubmed/34534292 http://dx.doi.org/10.1093/ijnp/pyab062 |
Ejemplares similares
-
Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects
por: Watanabe, Mai, et al.
Publicado: (2020) -
Rv0579 Is Involved in the Resistance to the TP053 Antitubercular Prodrug
por: Mori, Giorgia, et al.
Publicado: (2020) -
TP-CSO: A Triptolide Prodrug for Pancreatic Cancer Treatment
por: Wang, Xinlong, et al.
Publicado: (2022) -
Role of Serotonergic System in the Antidepressant Actions of mGlu2/3 Receptor Antagonists: Similarity to Ketamine
por: Chaki, Shigeyuki, et al.
Publicado: (2019) -
Assessment of Tp–e interval, Tp–e/QT, and Tp-e/QTc ratios in patients with acromegaly
por: ÇELİK, İbrahim Etem, et al.
Publicado: (2022)